Outstanding results have been obtained in the treatment of chronic myeloid leukemia (CML) with first-line imatinib therapy. However, approximately 35% of patients will not obtain long-term benefit with this approach. Allogeneic hematopoietic stem cell transplantation (HCT) is a valuable second-and third-line therapy for appropriately selected patients. To identify useful prognostic indicators of transplantation outcome in postimatinib therapeutic interventions, we investigated the role of the HCT comorbidity index (HCT-CI) together with levels of C-reactive protein (CRP) before HCT in 271 patients who underwent myeloablative HCT for CML in first chronic phase. Multivariate analysis showed both an HCT-CI score higher than 0 and CRP levels higher than 9 mg/L independently predict inferior survival and increased nonrelapse mortality at 100 days after HCT. CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib. IntroductionThe past decade has witnessed a dramatic change in the management of chronic myeloid leukemia (CML) such that the majority of patients initially receive therapy with imatinib rather than being offered allogeneic hematopoietic cell transplantation (HCT). 1 However, approximately 35% of these patients will fail to respond and/or develop intolerance. The treatment choices then include second-generation tyrosine kinase inhibitors and HCT, and the current challenge is to optimize the relative timings of these alternatives.The results of HCT in CML can be predicted using a prognostic score devised by the European Group for Blood and Marrow Transplantation (EBMT) based on 5 variables: donor type, disease phase, recipient age, donor/recipient sex combination, and interval from diagnosis to transplantation. 2 As the variable of disease phase resulted in higher relative risks than other variables in the model, 2 Passweg et al attempted to modify the score for patients in chronic phase for whom the decision of whether to undergo transplantation is most difficult. They found only one parameter with additional prognostic value, the Karnofsky performance score, and after inclusion the improvement over the original EBMT score was minimal. 3 The hematopoietic cell transplantation comorbidity index (HCT-CI) was developed to analyze the impact of comorbidities on outcome of HCT. 4 In several studies, the HCT-CI predicted for nonrelapse mortality (NRM) and overall survival (OS), 5-8 but it has never been studied specifically in patients with CML. C-reactive protein (CRP) is a sensitive marker of inflammation and persons with elevated levels of this acute phase protein are known to have an increased risk of cardiovascular diseases and malignancies. [9][10] We and others have previously shown the value of CRP levels shortly before HCT in predicting its outcomes. 11-12 However, it was unclear whether the elevated CRP was a reflection of an underlying comorbidity. In this study, we investigated the prognostic valu...

3392 Poster Board III-280 Although imatinib has replaced allogeneic stem cell transplantation (SCT) as the first treatment option for CML in first chronic phase (CP1), approximately 35% of patients do not obtain long-term benefit. As only 40-50% of these patients can be salvaged with second-generation tyrosine kinase inhibitors there is considerable debate about use of SCT as second line therapy. It is therefore important to identify groups of patients who would have a good outcome after SCT so that it may be offered after imatinib failure. In a previous analysis we identified the pre-conditioning level of C-reactive protein (CRP) as a prognostic factor for the outcome of SCT in CML. In this study, we investigated the prognostic value of comorbidities together with CRP at the time of myeloablative SCT, for patients with CML in CP1. Clinical data on 312 consecutive patients who underwent SCT between January 1991 and July 2008 was reviewed; 41 patients with incomplete data were omitted from the analysis. The median age of 271 analyzed patients was 34.3 years (range 9.7 – 59.6). 256 (94.5%) patients received bone marrow (BM) and 15 (5.5%) patients received peripheral blood stem cells (PBSC). Conditioning consisted of cyclophosphamide and TBI for 130 (48%) recipients of sibling stem cells. In addition in vivo T cell depletion with anti CD52 antibody (Campath 1H) was used for 141 (52%) unrelated donor transplants. Comorbidities were defined and assigned different weights (1-3) by the hematopoietic cell transplantation comorbidity index (HCT-CI; Sorror, ML et al, Blood 2005). HCT-CI scores were calculated for each patient stratifying them into low risk (LR, no comorbidities, HCT-CI =0), intermediate risk (IR, HCT-CI 1 or 2) and high risk (HR, HCT-CI ≥3) groups and were evaluated for their effects on transplant related mortality (TRM) and overall survival (OS). In multivariate analysis the HCT-CI score failed to predict OS or TRM at 1 year. The only significant difference was in TRM at 100 days between the patients with HCT-CI =0 (LR group) and patients with HCT-CI ≥1 (IR and HR groups; relative risk (RR) 4.0; 95% CI: 1.4 – 11.6). The absolute number of comorbidities (CMn) was a better prognostic indicator for day 100 TRM then the weighted HCT-CI (CMn=1, RR: 3.1, CI 1.3-7.3; CMn ≥1, RR: 4.9, CI: 1.7-14.1). Pre-conditioning CRP was predictive for both TRM and survival and was independent of CMn. We thus combined these two parameters into a new risk assessment tool (CRP/CMn), with 3 prognostic groups: LR (no comorbidities and CRP <2 mg/L), HR (1 comorbidity and CRP >10 mg/L or >1 comorbidity) and IR (remaining patients). These groups yielded probabilities of OS at 10 years of 81% (N=61, LR), 63% (N=159, IR) and 38% (N=25, HR; p=0.0001, Figure 1). When adjusted for patient age, duration of disease pre-SCT, donor type and patient/donor gender mismatch in a multivariate analysis, the relative risk of treatment failure (death) was 5.3 (95% CI: 2.5 – 11.5) for the HR group, and 2.3 (95% CI: 1.2 – 4.4) for the IR group when compared to the LR group. Fig 1 Probability of survival by CRP/CMn group Fig 1. Probability of survival by CRP/CMn group In our single center cohort of patients with CML in CP1 the HCT-CI was a poor indicator of prognosis post SCT. However, by removing the weighted scores and combining absolute number of co-morbidities with pre-conditioning CRP levels, we identified a new risk assessment tool that helps to select patients with CML in CP1 who could benefit from SCT as second line therapy. Disclosures: No relevant conflicts of interest to declare.